| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/0961203314555351 |
| P698 | PubMed publication ID | 25318969 |
| P50 | author | Annette Ladefoged de Thurah | Q57058740 |
| P2093 | author name string | M Nørgaard | |
| K Stengaard-Pedersen | |||
| J C Nørgaard | |||
| P2860 | cites work | Survival in systemic lupus erythematosus, 1995-2010. A prospective study in a Danish community | Q22299249 |
| A new method of classifying prognostic comorbidity in longitudinal studies: development and validation | Q29547376 | ||
| Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L) | Q31107094 | ||
| EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics | Q33284736 | ||
| Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients | Q33357081 | ||
| Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study | Q34017775 | ||
| Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus | Q34162739 | ||
| How to measure comorbidity. a critical review of available methods | Q34194168 | ||
| American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis | Q36221407 | ||
| Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis | Q36302245 | ||
| Problem pathogens: prevention of malaria in travellers | Q36406218 | ||
| Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004 | Q37069392 | ||
| Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review | Q37356697 | ||
| Epidemiology of atherosclerosis in systemic lupus erythematosus | Q37582574 | ||
| The role of antimalarial agents in the treatment of SLE and lupus nephritis | Q37947108 | ||
| Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects | Q38029146 | ||
| Evaluating the successful implementation of evidence into practice using the PARiHS framework: theoretical and practical challenges | Q38514627 | ||
| Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. | Q40461525 | ||
| Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual | Q41912319 | ||
| A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group | Q41926859 | ||
| Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. | Q41930670 | ||
| Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival | Q41941085 | ||
| Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus | Q41944460 | ||
| Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients | Q41945144 | ||
| Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. | Q43417859 | ||
| Immortal time bias in observational studies of drug effects | Q44123059 | ||
| The influence of the 1997 updated classification criteria for systemic lupus erythematosus: epidemiology, disease presentation, and patient management. | Q46125967 | ||
| Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups | Q46660881 | ||
| Occurrence of systemic lupus erythematosus in a Danish community: an 8-year prospective study. | Q50548860 | ||
| Systemic lupus erythematosus in Denmark: clinical and epidemiological characterization of a county-based cohort. | Q50561696 | ||
| Association of the Charlson comorbidity index with mortality in systemic lupus erythematosus. | Q51030874 | ||
| High incidence and prevalence of systemic lupus erythematosus in Norway. | Q51191137 | ||
| Medication use in systemic lupus erythematosus. | Q51637087 | ||
| P433 | issue | 3 | |
| P921 | main subject | Denmark | Q35 |
| antimalarial | Q521616 | ||
| P304 | page(s) | 299-306 | |
| P577 | publication date | 2014-10-15 | |
| P1433 | published in | Lupus | Q6704846 |
| P1476 | title | Antimalarials in the treatment of systemic lupus erythematosus: a registry-based cohort study in Denmark | |
| P478 | volume | 24 |
| Q50571191 | Cutaneous lupus erythematosus and systemic lupus erythematosus are associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. |
| Q33434719 | Disease flare patterns and predictors of systemic lupus erythematosus in a monocentric cohort of 423 Japanese patients during a long-term follow-up: The JUDE study |
| Q30490276 | First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study. |
| Q39454212 | Prevalence of maternal chronic diseases during pregnancy - a nationwide population based study from 1989 to 2013. |
| Q34498515 | Systemic lupus erythematosus: review of synthetic drugs |
Search more.